The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Subscribe To Our Newsletter & Stay Updated
